Minor impairment of oral iron absorption in non-diabetic new dialysis patients

Journal of Nephrology

Volumn 18, Issue 2, 2005, Pages 174-180

  Tovbin, David ^a   Schnaider, Alla ^a   Vorobiov, Marina ^a   Rogachev, Boris ^a   Basok, Anna ^a   Shull, Philip ^b   Novack, Victor ^a   Friger, Michael ^a   Avramov, Dan ^a   Zlotnik, Moshe ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Absorption; Anemia; Diabetes mellitus; End stage renal disease duration; Hemodialysis; Intradialytic; Intradialytic iron absorption; Iron; Iron absorption; Oral iron

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; FERRIPEL; FERRITIN; IRON; IRON POLYMALTOSE; PARATHYROID HORMONE; TRANSFERRIN;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BLOOD VOLUME; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRY WEIGHT; FEMALE; HEMODIALYSIS; HUMAN; IRON ABSORPTION; KIDNEY FAILURE; MALE; MEDICAL ASSESSMENT; SEX DIFFERENCE; TREATMENT OUTCOME; ULTRAFILTRATION;

ADMINISTRATION, ORAL; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS; TRANSFERRIN;

EID: 20744436504     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Murphy ST, Parfrey PS. The impact of anemia correction on cardiovascular disease in end-stage renal disease. Semin Nephrol 2000; 20: 350-5.
2. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano E. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000; 11: 335-42.
3. K/DOQI Guidelines 2000, guideline 8. Am J Kidney Dis 2001; 37 (suppl 1): S182-238.
4. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int 1999; 69 (suppl): S61-6.
5. Macdougall IC, Horl WH, Jacobs C, Valderrabano F, Parrondo I, Thompson K, Cremers S. European best practice guidelines 6-8: assessing and optimizing iron stores. Nephrol Dial Transplant 2000; 15 (suppl 4): S20-32.
6. Goch J, Birgegard G, Danielson BG, Wikstrom B. Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test. Nephron 1996; 73: 403-6.
7. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 1998; 13: 82-8.
8. Deira J, Martin M, Sanchez S, Garrido J, Nunez J, Tabernero JM. Evaluation of intestinal iron absorption by indirect methods in patients on hemodialysis receiving oral iron and recombinant human erythropoietin. Am J Kidney Dis 2002; 39: 594-9.
9. Tovbin D, Markowitz A, Landver R, Mostoslavsky M. Effective erythropoiesis on supervised intradialytic oral iron and vitamin C therapy is correlated with Kt/V and patient weight. Clin Nephrol 2000; 53: 276-82.
10. Kooistra MP, Kersting S, Gosriwatana I, Lu S, Nijhoff-Schutte J, Hider RC, Marx JJ. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002; 32 (suppl 1): S36-41.
11. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9: 655-63.
12. Sunder-Plassmann G, Patruta SI, Horl WH. Patho-biology of the role of iron in infection. Am J Kidney Dis 1999; 34 (suppl 2): S25-9.
13. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11: 539-49.
14. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-7.
15. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 2002; 40: 1005-12.
16. Jimenez RE, Price DA, Pinkus GS, Owen WF Jr, Lazarus JM, Kay J, Turner JR. Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis. Am J Surg Pathol 1998; 22: 729-35.
17. Okechukwu CN, Lopes AA, Stack AG, Feng S, Wolfe RA, Port FK. Impact of years of dialysis therapy on mortality risk and the characteristics of longer term dialysis survivors. Am J Kidney Dis 2002; 39: 533-8.
18. Chertow GM, Plone M, Dillon MA, Burke SK, Slatopolsky E. Hyperparathyroidism and dialysis vintage. Clin Nephrol 2000; 54: 295-300.
19. Chertow GM, Johansen KL, Lew N, Lazarus JM, Lowrie EG. Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int 2000; 57: 1176-81.
20. Zoccali C, Mallamaci F, Tripepi G. AGEs and carbonyl stress: potential pathogenetic factors of long-term uraemic complications. Nephrol Dial Transplant 2000; 15 (suppl 2): S7-11
21. Lynch SR. Interaction of iron with other nutrients. Nutr Rev 1997; 55: 102-10.
22. Bastani B, Islam S, Boroujerdi N. Iron absorption after single pharmacological oral iron loading test in patients on chronic peritoneal dialysis and healthy volunteers. Perit Dial Int 2000; 20: 662-6.
23. Dittrich E, Puttinger H, Schneider B, Horl WH, Haag-Weber M, Vychytil A. Is absorption of high-dose oral iron sufficient in peritoneal dialysis patients? Perit Dial Int 2000; 20: 667-73.